{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:05:07Z","timestamp":1780463107024,"version":"3.54.1"},"reference-count":90,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2023,6,21]],"date-time":"2023-06-21T00:00:00Z","timestamp":1687305600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Risk Analysis"],"published-print":{"date-parts":[[2024,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Due to the very low, but nonzero, paralysis risks associated with the use of oral poliovirus vaccine (OPV), eradicating poliomyelitis requires ending all OPV use globally. The Global Polio Eradication Initiative (GPEI) coordinated cessation of Sabin type 2 OPV (OPV2 cessation) in 2016, except for emergency outbreak response. However, as of early 2023, plans for cessation of bivalent OPV (bOPV, containing types 1 and 3 OPV) remain undefined, and OPV2 use for outbreak response continues due to ongoing transmission of type 2 polioviruses and reported type 2 cases. Recent development and use of a genetically stabilized novel type 2 OPV (nOPV2) leads to additional potential vaccine options and increasing complexity in strategies for the polio endgame. Prior applications of integrated global risk, economic, and poliovirus transmission modeling consistent with GPEI strategic plans that preceded OPV2 cessation explored OPV cessation dynamics and the evaluation of options to support globally coordinated risk management efforts. The 2022\u20132026 GPEI strategic plan highlighted the need for early bOPV cessation planning. We review the published modeling and explore bOPV cessation immunization options as of 2022, assuming that the GPEI partners will not support restart of the use of any OPV type in routine immunization after a globally coordinated cessation of such use. We model the potential consequences of globally coordinating bOPV cessation in 2027, as anticipated in the 2022\u20132026 GPEI strategic plan. We do not find any options for bOPV cessation likely to succeed without a strategy of bOPV intensification to increase population immunity prior to cessation.<\/jats:p>","DOI":"10.1111\/risa.14158","type":"journal-article","created":{"date-parts":[[2023,6,24]],"date-time":"2023-06-24T05:16:41Z","timestamp":1687583801000},"page":"366-378","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Coordinated global cessation of oral poliovirus vaccine use: Options and potential consequences"],"prefix":"10.1111","volume":"44","author":[{"given":"Dominika A.","family":"Kalkowska","sequence":"first","affiliation":[{"name":"Kid Risk Inc.  Orlando Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven G. F.","family":"Wassilak","sequence":"additional","affiliation":[{"name":"Global Immunization Division Center for Global Health, Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Wiesen","sequence":"additional","affiliation":[{"name":"Global Immunization Division Center for Global Health, Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cara C.","family":"Burns","sequence":"additional","affiliation":[{"name":"Division of Viral Diseases National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1015-4818","authenticated-orcid":false,"given":"Mark A.","family":"Pallansch","sequence":"additional","affiliation":[{"name":"National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention  Atlanta Georgia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4900-9455","authenticated-orcid":false,"given":"Kamran","family":"Badizadegan","sequence":"additional","affiliation":[{"name":"Kid Risk Inc.  Orlando Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0849-9147","authenticated-orcid":false,"given":"Kimberly M.","family":"Thompson","sequence":"additional","affiliation":[{"name":"Kid Risk Inc.  Orlando Florida USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2023,6,21]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2004.02.009"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc4262"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2214\u2010109X(21)00205\u20109"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro1769"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010016\u20101537\u20108"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010016\u20101536\u20109"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010018\u20103074\u20100"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen\u20102018\u2010023938"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.12962"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010015\u20101112\u20108"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1539\u20106924.2006.00827.x"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/aje\/kwi206"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010016\u20101465\u20107"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit838"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010015\u20101114\u20106"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2017.1322514"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2018.1506333"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.4172\/2157\u20107560.1000340"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n1818"},{"key":"e_1_2_8_21_1","unstructured":"Global Polio Eradication Initiative. (2020).GPEI consultation with OPV\/IPV manufacturers national authorities for containment and national regulatory authorities.https:\/\/polioeradication.org\/wp\u2010content\/uploads\/2022\/01\/2020\u2010GPEI\u2010Consultation\u2010with\u2010OPV\u2010IPV\u2010Manufacturers\u2010NACs\u2010NRAs.pdf"},{"key":"e_1_2_8_22_1","unstructured":"Global Polio Eradication Initiative. (2022).Somalia.https:\/\/polioeradication.org\/where\u2010we\u2010work\/somalia\/"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590\u2010021\u201001054\u20105"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(04)17351\u20100"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(22)01274\u20100"},{"key":"e_1_2_8_26_1","doi-asserted-by":"crossref","unstructured":"Kalkowsa D. A. Wassilak S. G. F. Wiesen E. Estivariz C. F. Burns C. C. Badizadegan K. &Thompson K. M.(2023).Complexity of options related to restarting oral poliovirus vaccine (OPV) in national immunization programs after OPV cessation [version 1; peer review: awaiting peer review].Gates Open Res https:\/\/gatesopenresearch.org\/articles\/7\u201055","DOI":"10.12688\/gatesopenres.14511.1"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13983"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13982"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiu674"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010015\u20100791\u20105"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13214"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13193"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13555"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab160"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13447"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.04.061"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13622"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13590"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13664"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.04.026"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.10.060"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41541\u2010020\u20100176\u20107"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7133e2"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aba1238"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2022.02.050"},{"key":"e_1_2_8_46_1","unstructured":"Relief Web. (2022).UNICEF Yemen humanitarian situation report: 1\u201331 March 2022.https:\/\/reliefweb.int\/report\/yemen\/unicef\u2010yemen\u2010humanitarian\u2010situation\u2010report\u20101\u201031\u2010march\u20102022"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7144e2"},{"issue":"4","key":"e_1_2_8_48_1","first-page":"35","article-title":"Policy decision options during the first 5 years following certification of polio eradication","volume":"5","author":"Sangrujee N.","year":"2003","journal-title":"Medscape General Medicine"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13668"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1473\u20103099(21)00458\u20108"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2022.2017287"},{"issue":"8","key":"e_1_2_8_52_1","first-page":"190","article-title":"The case for cooperation in managing and maintaining the end of poliomyelitis: Stockpile needs and coordinated OPV cessation","volume":"10","author":"Thompson K. M.","year":"2008","journal-title":"Medscape Journal of Medicine"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jit845"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2014.864563"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010015\u20101113\u20107"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879\u2010015\u20101116\u20104"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix128"},{"key":"e_1_2_8_58_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix108"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1539\u20106924.2006.00843.x"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2019.1635463"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2020.1791093"},{"key":"e_1_2_8_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13557"},{"key":"e_1_2_8_63_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13484"},{"key":"e_1_2_8_64_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13614"},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2021.1891889"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.13671"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2022.2128108"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.1098419"},{"key":"e_1_2_8_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2015.02.013"},{"key":"e_1_2_8_70_1","doi-asserted-by":"publisher","DOI":"10.1111\/risa.12019"},{"key":"e_1_2_8_71_1","doi-asserted-by":"publisher","DOI":"10.1586\/erv.11.195"},{"key":"e_1_2_8_72_1","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2007.122192"},{"key":"e_1_2_8_73_1","doi-asserted-by":"publisher","DOI":"10.1177\/003335491212700104"},{"key":"e_1_2_8_74_1","unstructured":"United Kingdom Department of Health & Social Care. (2022).Joint Committee on Vaccination and Immunisation statement on vaccination strategy for the ongoing polio incident.https:\/\/www.gov.uk\/government\/publications\/vaccination\u2010strategy\u2010for\u2010ongoing\u2010polio\u2010incident\u2010jcvi\u2010statement\/joint\u2010committee\u2010on\u2010vaccination\u2010and\u2010immunisation\u2010statement\u2010on\u2010vaccination\u2010strategy\u2010for\u2010the\u2010ongoing\u2010polio\u2010incident"},{"key":"e_1_2_8_75_1","unstructured":"World Health Assembly. (2008).Poliomyelitis: Mechanism for management of potential risks to eradication (resolution 61.1) WHO Geneva 19\u201324 May 2008. World Health Organization.http:\/\/apps.who.int\/gb\/ebwha\/pdf_files\/WHA61\u2010REC1\/A61_Rec1\u2010part2\u2010en.pdf"},{"key":"e_1_2_8_76_1","unstructured":"World Health Organization. (1997).Global eradication of poliomyelitis: Report of the second meeting of the Global Technical Consultative Group (TCG) 28 April 1997. Department of Vaccines and Biologicals World Health Organization.https:\/\/apps.who.int\/iris\/bitstream\/handle\/10665\/63994\/WHO_EPI_GEN_98.04.pdf"},{"issue":"50","key":"e_1_2_8_77_1","first-page":"561","article-title":"Meeting of the Strategic Advisory Group of Experts on immunization, October 2014\u2014Conclusions and recommendations","volume":"89","author":"World Health Organization","year":"2014","journal-title":"Weekly Epidemiological Record"},{"key":"e_1_2_8_78_1","unstructured":"World Health Organization. (2015a).14th Meeting of the Global Commission for Certification of Poliomyelitis Eradication (GCC) Bali Indonesia 20\u201321 September 2015 Summary of findings decisions and recommendations.http:\/\/polioeradication.org\/wp\u2010content\/uploads\/2016\/07\/1Report.pdf"},{"issue":"50","key":"e_1_2_8_79_1","first-page":"681","article-title":"Meeting of the Strategic Advisory Group of Experts on immunization, October 2015\u2014Conclusions and recommendations","volume":"90","author":"World Health Organization","year":"2015","journal-title":"Weekly Epidemiological Record"},{"key":"e_1_2_8_80_1","unstructured":"World Health Organization. (2019).Report from the Twentieth Meeting of the Global Commission for Certification of Poliomyelitis Eradication Geneva Switzerland 17\u201318 October 2019.http:\/\/polioeradication.org\/wp\u2010content\/uploads\/2016\/07\/20th\u2010meeting\u2010of\u2010the\u2010Global\u2010Commission\u2010for\u2010the\u2010Certification\u2010of\u2010Eradication\u2010of\u2010Poliomyelitis\u201017\u201018\u2010October\u20102019.pdf"},{"issue":"24","key":"e_1_2_8_81_1","first-page":"274","article-title":"Meeting of the Strategic Advisory Group of Experts on immunization, April 2022: Conclusions and recommendations","volume":"97","author":"World Health Organization","year":"2022","journal-title":"Weekly Epidemiological Record"},{"key":"e_1_2_8_82_1","unstructured":"World Health Organization. (2022b).Report from the Twenty\u2010Second Meeting of the Global Commission for Certification of Poliomyelitis Eradication Geneva Switzerland 3 June 2022.https:\/\/polioeradication.org\/wp\u2010content\/uploads\/2022\/09\/22nd\u2010GCC\u2010report\u201020220907.pdf"},{"key":"e_1_2_8_83_1","unstructured":"World Health Organization. (2023).Wild poliovirus list: List of wild poliovirus by country and year. Retrieved April 3 2023 fromhttps:\/\/polioeradication.org\/polio\u2010today\/polio\u2010now\/wild\u2010poliovirus\u2010list\/"},{"key":"e_1_2_8_84_1","unstructured":"World Health Organization and UNICEF. (2018).17th WHO\/UNICEF consultation with OPV\/IPV manufacturers and national authorities for containment of polio vaccine producing countries.http:\/\/polioeradication.org\/wp\u2010content\/uploads\/2018\/11\/2018_WHO_UNICEF_Consultation_Mtg_Report_FINAL.pdf"},{"key":"e_1_2_8_85_1","unstructured":"World Health Organization Global Polio Eradication Initiative. (2013).Polio eradication and endgame strategic plan (2013\u20102018).http:\/\/polioeradication.org\/wp\u2010content\/uploads\/2016\/07\/PEESP_EN_A4.pdf"},{"key":"e_1_2_8_86_1","unstructured":"World Health Organization Global Polio Eradication Initiative. (2016).Standard operating procedures: Responding to a poliovirus event or outbreak: Part 1: General SOPs.https:\/\/s3.amazonaws.com\/gpei\u2010tk\/reference_links\/en\/GPEI_SOPs.pdf"},{"key":"e_1_2_8_87_1","unstructured":"World Health Organization Global Polio Eradication Initiative. (2020).Interim guidance on the use of novel oral polio vaccine type 2 (nOPV2) for the response to type 2 circulating vaccine\u2010derived poliovirus (cVDPV2) during the initial use period (Addendum to the standard operating procedures for response to a poliovirus event or outbreak version 3.1).https:\/\/polioeradication.org\/wp\u2010content\/uploads\/2020\/11\/EN\u2010interim\u2010Guidance\u2010on\u2010the\u2010use\u2010of\u2010nOPV2\u2010during\u2010the\u2010initial\u2010use\u2010period\u2010Oct2020.pdf"},{"key":"e_1_2_8_88_1","unstructured":"World Health Organization Global Polio Eradication Initiative. (2021).Polio eradication strategy 2022\u20132026: Delivering on a promise.https:\/\/polioeradication.org\/wp\u2010content\/uploads\/2022\/06\/Polio\u2010Eradication\u2010Strategy\u20102022\u20102026\u2010Delivering\u2010on\u2010a\u2010Promise.pdf"},{"key":"e_1_2_8_89_1","unstructured":"World Health Organization Global Polio Eradication Initiative. (2023).Circulating vaccine\u2010derived poliovirus.https:\/\/polioeradication.org\/wp\u2010content\/uploads\/2023\/03\/weekly\u2010polio\u2010analyses\u2010cVDPV\u201020230328.pdf"},{"key":"e_1_2_8_90_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.04.003"},{"key":"e_1_2_8_91_1","doi-asserted-by":"publisher","DOI":"10.2807\/1560\u20107917.ES.2022.27.37.2200694"}],"container-title":["Risk Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/risa.14158","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T06:51:16Z","timestamp":1706770276000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/risa.14158"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,21]]},"references-count":90,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["10.1111\/risa.14158"],"URL":"https:\/\/doi.org\/10.1111\/risa.14158","archive":["Portico"],"relation":{},"ISSN":["0272-4332","1539-6924"],"issn-type":[{"value":"0272-4332","type":"print"},{"value":"1539-6924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,6,21]]},"assertion":[{"value":"2023-06-21","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}